Tempest Therapeutics
TPST
73 hedge funds and large institutions have $854M invested in Tempest Therapeutics in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 3 closing their positions.
733% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 3
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
250% more capital invested
Capital invested by funds: $244M → $854M (+$610M)
38% more funds holding
Funds holding: 53 → 73 (+20)
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.5M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$8.71M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.79M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$4.76M |
| 5 |
JP Morgan Chase
New York
|
+$4.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$12.7M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.1M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$3.37M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$2.49M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.42M |
TPST Hedge Fund Activity: Q4 2014 in Review
73 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2014, worth a combined $854M — up 250% from $244M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TPST positions and 3 closed out — a net gain of 22 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.5M. The largest seller was Deerfield Management, cutting an estimated $12.7M.
- 73 institutional investors held Tempest Therapeutics (TPST) as of Q4 2014, up from 53 in Q3 2014.
- Funds reported $854M of Tempest Therapeutics stock for Q4 2014, up 250% quarter-over-quarter.
- 25 funds opened new Tempest Therapeutics positions in Q4 2014 and 3 closed out, a net change of +22 holders.
- The largest Tempest Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $18.5M added.
- The largest Tempest Therapeutics seller in Q4 2014 was Deerfield Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q4 2014.